Lansoprazole

Lansoprazole
Systematic (IUPAC) name
(RS)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
Clinical data
Trade names Prevacid
AHFS/Drugs.com monograph
MedlinePlus a695020
Licence data US FDA:link
Pregnancy cat. B3 (AU) B (US)
Legal status OTC (US) Rx Only
Routes Oral, IV
Pharmacokinetic data
Bioavailability 80% or more
Protein binding 97%
Metabolism Hepatic (CYP3A4- and CYP2C19-mediated)
Half-life 1–1.5 hours
Excretion Renal and fecal
Identifiers
CAS number 103577-45-3 YesY
ATC code A02BC03
PubChem CID 3883
DrugBank DB00448
ChemSpider 3746 YesY
UNII 0K5C5T2QPG YesY
KEGG D00355 YesY
ChEBI CHEBI:6375 YesY
ChEMBL CHEMBL480 YesY
Chemical data
Formula C16H14F3N3O2S 
Mol. mass 369.363 g/mol
SMILES eMolecules & PubChem
 YesY (what is this?)  (verify)

Lansoprazole (play /lænˈsprəzl/ lan-SOH-prə-zohl; INN) is a proton-pump inhibitor (PPI) which inhibits the stomach's production of gastric acids. It is manufactured by a number of companies worldwide under several brand names. In the United States it was first approved by the Food and Drug Administration (FDA) in 1995.[1]

Lansoprazole has been available as a generic drug since Prevacid patent protection expired on November 10, 2009.[2][3] Since 2009 Lansoprazole has been available over the counter (OTC) in the U.S. in a 15 mg dose marketed by Novartis as Prevacid 24HR.[4][5][6]

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.[7] Lansoprazole is a racemate [1:1-mixture of the enantiomers dexlansoprazole (Kapidex) and levolansoprazole].[8] Dexlanprantazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,[9] and the effects of the drug last for over 24 hours after it has been used for 1 day or more.[10] Lansoprazole, 30 mg administered nasogastrically, effectively controls intragastric pH and is an alternative to i.v. pantoprazole in patients who are unable to swallow solid dosage formulations.[11]

Indications

Lansoprazole is indicated for:

Drug interactions

Lansoprazole interacts with several other drugs, either due to its own nature or as a proton pump inhibitor[12].

Side effects

Side effects of proton pump inhibitors in general[14] and lansoprazole in particular[15] may include:

Proton-pump inhibitors may be associated with a greater risk of hip fractures[18] and Clostridium difficile-associated diarrhea.[19] Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.[20]

Brand names

Prevacid 30 mg

Lansoprazole is available as a generic drug in the US, UK, Canada, Belgium, Finland,[21] France, Colombia, Italy, Sweden,[22] and Mexico.[citation needed]

The drug is also sold under several brand names, including:[1]

References

  1. ^ a b Mosby's Drug Consult: Lansoprazole
  2. ^ Prevacid drug patents
  3. ^ Teva to release Prevacid version when patent expires
  4. ^ "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (PDF) (Press release). November 12, 2009. http://www.prevacid24hr.com/pdfs/News%20media%20release%20-%20Prevacid24HR%20Launch%20-%20November%202009.pdf. Retrieved 2009-11-13. 
  5. ^ "Prevacid 24HR Patient Package Insert" (PDF). November 12, 2009. http://www.prevacid24hr.com/pdfs/PackageInsert.pdf. Retrieved 2009-11-13. 
  6. ^ "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (Press release). November 12, 2009. http://www.novartis.com/newsroom/media-releases/en/2009/1354451.shtml. Retrieved 2009-11-13. 
  7. ^ http://www.patient.co.uk/showdoc/30002943/
  8. ^ http://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings/pharmacy-benefit-update-summer-fall-2009.pdf
  9. ^ a b "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. http://www.rxlist.com/cgi/generic/lansop_cp.htm. Retrieved 2007-04-14. 
  10. ^ "Prevacid 24HR Fact Sheet" (PDF). November 12, 2009. http://www.prevacid24hr.com/pdfs/Prevacid24HR_Product_Fact_Sheet.pdf. Retrieved 2009-11-13. 
  11. ^ Effects on 24-Hour Intragastric pHFreston M.D., Ph.D., James; Yi-Lin Chiu, Ph.D., Wei-Jian Pan, Ph.D., Nancy Lukasik, B.S.N., and Jörg Täubel, M.D., A.F.P.M. (2001). "Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously". American Journal of Gastroenterology 96 (7): 2058–2065. doi:10.1111/j.1572-0241.2001.03939.x. ISSN 0002-9270. OCLC 440925790. PMID 11467632. 
  12. ^ British National Formulary (Free registration required) Lansoprazole interactions
  13. ^ Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag [1]
  14. ^ British National Formulary (Free registration required) 1.3.5 Proton pump inhibitors
  15. ^ British National Formulary (Free registration required) Lansoprazole
  16. ^ K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225
  17. ^ Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL. Dermatology. St. Louis: Mosby. p. 154. ISBN 1-4160-2999-0. .
  18. ^ Yang YX, Lewis JD, Epstein S, Metz DC (December 2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA 296 (24): 2947–53. doi:10.1001/jama.296.24.2947. PMID 17190895. 
  19. ^ "Proton pump inhibitors and Clostridium difficile". Bandolier. 2003. http://www.medicine.ox.ac.uk/bandolier/booth/Pharmacy/PPIcdiff.html. Retrieved 2007-07-13. 
  20. ^ Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (May 2009). "Acid-suppressive medication use and the risk for hospital-acquired pneumonia". JAMA 301 (20): 2120–8. doi:10.1001/jama.2009.722. PMID 19470989. 
  21. ^ "Vastaavat tuotteet - hintavertailu" (in Finnish). http://www.terveyskirjasto.fi/terveysportti/geneerinen.substituutio?p_ryhma=0000130030. 
  22. ^ "FASS.se, accessed 2010-02-13" (in Swedish). http://www.fass.se/LIF/produktfakta/substance_products.jsp?substanceId=IDE4POFNUB4MJVERT1. 

External links